Is DSIP (Intranasal) appropriate alongside SSRIs or other psychiatric medications?

DSIP (Intranasal)'s pharmacology is generally additive rather than competitive with most psychiatric medications, but the combined modulation of monoamine systems warrants supervision. Users on SSRIs, SNRIs, lithium, or atypical antipsychotics should consult their prescriber before adding DSIP (Intranasal) to the regimen.

Does DSIP (Intranasal) cross the blood-brain barrier?

Direct BBB passage is variable across peptide compounds and is rarely the dominant mechanism. DSIP (Intranasal) produces CNS effects through some combination of: direct BBB transport (at low efficiency for most peptides), vagal-afferent gut-brain axis signalling, and effects on cerebral vasculature where the barrier is locally compromised. The CNS effects observed in research consistently appear at peripheral doses, supporting the indirect-access framework.

Is DSIP (Intranasal) appropriate alongside SSRIs or other psychiatric medications?

DSIP (Intranasal)'s pharmacology is generally additive rather than competitive with most psychiatric medications, but the combined modulation of monoamine systems warrants supervision. Users on SSRIs, SNRIs, lithium, or atypical antipsychotics should consult their prescriber before adding DSIP (Intranasal) to the regimen.

Does DSIP (Intranasal) cross the blood-brain barrier?

Direct BBB passage is variable across peptide compounds and is rarely the dominant mechanism. DSIP (Intranasal) produces CNS effects through some combination of: direct BBB transport (at low efficiency for most peptides), vagal-afferent gut-brain axis signalling, and effects on cerebral vasculature where the barrier is locally compromised. The CNS effects observed in research consistently appear at peripheral doses, supporting the indirect-access framework.

Does DSIP (Intranasal) cross the blood-brain barrier?

Direct BBB passage is variable across peptide compounds and is rarely the dominant mechanism. DSIP (Intranasal) produces CNS effects through some combination of: direct BBB transport (at low efficiency for most peptides), vagal-afferent gut-brain axis signalling, and effects on cerebral vasculature where the barrier is locally compromised. The CNS effects observed in research consistently appear at peripheral doses, supporting the indirect-access framework.

Is DSIP (Intranasal) appropriate alongside SSRIs or other psychiatric medications?

DSIP (Intranasal)'s pharmacology is generally additive rather than competitive with most psychiatric medications, but the combined modulation of monoamine systems warrants supervision. Users on SSRIs, SNRIs, lithium, or atypical antipsychotics should consult their prescriber before adding DSIP (Intranasal) to the regimen.

What does DSIP (Intranasal) stack well with?

For cognitive / neurological protocols, DSIP (Intranasal) pairs with compounds on complementary pathways: Semax, Selank, Semax + Selank Blend. These pairings are selected because they engage independent receptor systems from DSIP (Intranasal)'s primary mechanism (Same DSIP molecule delivered intranasally), producing additive or synergistic effects rather than receptor competition.

What is the standard dosing protocol for DSIP (Intranasal)?

Conventional DSIP (Intranasal) dosing is 100-300 mcg 1 spray before sleep via intranasal. For cognitive and neurological use specifically, the cycle pattern is typically 8–12 weeks on followed by a 4 week off-period. Higher doses are studied in advanced protocols but produce diminishing dose-response in the published literature.

What is the regulatory status of DSIP (Intranasal)?

DSIP (Intranasal) regulatory status: Unapproved in the United States; WADA status not on prohibited list; research level preclinical. Clinical access for off-label use is via compounded prescription where permissible. International regulatory status varies by jurisdiction. For cognitive and neurological use specifically, the regulatory profile shapes which monitoring and supervision approaches are required.

How does DSIP (Intranasal)'s half-life affect dosing?

DSIP (Intranasal) has a plasma half-life of Rapid CNS uptake via olfactory route, which is moderate, supporting once-daily dosing in most protocols. The receptor occupancy curve under 1 spray before sleep dosing at 100-300 mcg per dose explains the typical onset timeline for cognitive and neurological endpoints.

What is the mechanism of action of DSIP (Intranasal)?

Same DSIP molecule delivered intranasally. The olfactory and trigeminal nerve pathways allow direct CNS access, sidestepping the BBB and producing faster onset on sleep-relevant brain regions. For cognitive and neurological applications specifically, the relevant downstream consequence is the cascade from receptor engagement to systemic effect: Same DSIP molecule delivered intranasally. The cognitive / neurological interpretation focuses on the pathway-level detail rather than on any single high-level summary.

Home/ Compounds/ DSIP (Intranasal)

DSIP (Intranasal)

Neuroprotection

Neurology research on DSIP (Intranasal) examines whether this neuropeptide (sleep, intranasal) produces measurable CNS effects beyond peripheral activity. The cognitive case rests on three convergent threads: same dsip molecule delivered intranasally the olfactory and trigeminal nerve pathways allow direct cns access, sidestepping the bbb and producing faster onset on sleep-relevant brain regions.; downstream consequences for monoamine and neurotrophic signalling; and reduction of chronic neuroinflammation. DSIP (Intranasal) is dosed at 100-300 mcg 1 spray before sleep via intranasal in cognitive-focused protocols, with the Rapid CNS uptake via olfactory route pharmacokinetic profile shaping receptor occupancy timing.

Cognitive / Neurological Applications

Chronic NeuroinflammationNeurogenesisPost-TBI RecoveryMood StabilisationStroke Recovery

Key Takeaways

Cognitive lens: DSIP (Intranasal) acts as a restorative compound rather than a stimulant for cognitive endpoints.
CNS access pattern: BBB transport plus vagal-afferent gut-brain signalling and cerebral vascular effects.
Mechanism: Same DSIP molecule delivered intranasally.
Neuro dose: 100-300 mcg 1 spray before sleep via intranasal; cognitive effects accumulate across 4-8 weeks.
Cognitive stack partners: Semax, Selank, Semax + Selank Blend.

Cognitive / Neurological Mechanism

DSIP (Intranasal)'s neurological relevance starts with how the compound reaches the central nervous system. Same DSIP molecule delivered intranasally. The olfactory and trigeminal nerve pathways allow direct CNS access, sidestepping the BBB and producing faster onset on sleep-relevant brain regions. Direct blood-brain barrier transport is rarely the dominant route for peptide compounds; vagal-afferent gut-brain signalling and effects on cerebral vasculature where the barrier is locally compromised typically produce the CNS phenotype. The detail follows.

Cerebral perfusion and the structural cognitive substrate

Cognitive function depends on adequate cerebral perfusion, intact endothelial signalling, and a low chronic-inflammatory tone in the brain parenchyma. DSIP (Intranasal), with its Same DSIP molecule delivered intranasally The olfactory and trigeminal nerve pathways allow direct CNS access, sidestepping the BBB and producing faster onset on sleep-relevant brain regions. mechanism, contributes to this substrate rather than producing acute stimulant-like activation. Across the cognitive applications outlined below, what users describe is restoration of baseline rather than amplification above it. The Rapid CNS uptake via olfactory route pharmacokinetic profile supports this restorative rather than stimulant phenotype.

Inflammation and neurological recovery

One of the most replicated effects across compounds in DSIP (Intranasal)'s class (Neuropeptide (sleep, intranasal)) is reduction of inflammatory cytokines (TNF-α, IL-1β, IL-6) in tissues including the central nervous system. For users whose cognitive complaints track with chronic low-grade neuroinflammation — long-COVID, post-viral cognitive fog, post-concussion lingering symptoms, chronic stress — this anti-inflammatory layer is often the most operationally relevant mechanism. DSIP (Intranasal)'s contribution operates on the same axis at 100-300 mcg per dose.

Receptor pharmacology and selectivity profile

DSIP (Intranasal)'s receptor-level pharmacology determines its selectivity profile and its overlap with companion peptides. Same DSIP molecule delivered intranasally. The olfactory and trigeminal nerve pathways allow direct CNS access, sidestepping the BBB and producing faster onset on sleep-relevant brain regions. The selectivity (or lack thereof) for the principal target relative to off-target receptors is the basis for both the clinical phenotype and the side-effect profile. In stack design this matters: pairing DSIP (Intranasal) with peptides engaging the same primary receptor produces competition rather than synergy.

Cognitive / Neurological Applications

Gut-Brain Axis

Where DSIP (Intranasal) is used for gut-brain axis, the dosing window is typically 4–8 weeks with re-evaluation at the end of cycle. Stacking with selank or semax is common in this use case; pure-isolated dosing is also viable for first-cycle users.

Post-TBI Recovery

Post-TBI Recovery is one of the more-reported subjective benefits of DSIP (Intranasal) across cognitive-focused user cohorts. The mechanism is plausible given the compound's neurotrophic and anti-inflammatory profile; the effect size depends substantially on baseline status.

Dopamine Modulation

For dopamine modulation, DSIP (Intranasal) is most-relevant in users whose cognitive complaints track with chronic neuroinflammation or post-injury recovery. Effect size is modest but consistent across well-tolerated dose ranges, with typical response window of 4–8 weeks.

Mood Stabilisation

Where DSIP (Intranasal) is used for mood stabilisation, the dosing window is typically 4–8 weeks with re-evaluation at the end of cycle. Stacking with selank or semax is common in this use case; pure-isolated dosing is also viable for first-cycle users.

Dosing Protocol

Goal	Route	Dose	Cycle
Standard protocol	Intranasal	100-300 mcg	8–12 weeks on / 4 weeks off
Conservative starter	Intranasal	60-300 mcg	4–6 weeks initial cycle
Neuroprotection focus	Intranasal	100-300 mcg	1 spray before sleep
Maintenance phase	Intranasal	70-300 mcg	Ongoing with periodic pauses

Dose timing for DSIP (Intranasal) is less time-sensitive given the longer half-life. Consistency through the cycle is more important than the precise clock time of individual doses.

Stacking

DSIP (Intranasal) stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from the cognitive neuroscience community.

DSIP (Intranasal) + Semax: Elevates BDNF and NGF in hippocampus and cortex. Pairs naturally with DSIP (Intranasal)'s mechanism in cognitive / neurological protocols.
DSIP (Intranasal) + Selank: Modulates GABA-A receptor systems indirectly. Pairs naturally with DSIP (Intranasal)'s mechanism in cognitive / neurological protocols.
DSIP (Intranasal) + Semax + Selank Blend: Semax raises BDNF and modulates dopamine systems; Selank stabilises GABAergic and serotonergic tone. Pairs naturally with DSIP (Intranasal)'s mechanism in cognitive / neurological protocols.
DSIP (Intranasal) + DSIP: Mechanism remains incompletely characterised. Pairs naturally with DSIP (Intranasal)'s mechanism in cognitive / neurological protocols.

Safety & Regulatory Status

WADA: Not on prohibited list FDA: Unapproved Research: Preclinical

Excellent tolerability. Mild nasal irritation possible.

Lens-specific safety considerations for cognitive / neurological use of DSIP (Intranasal): Excellent tolerability. Mild nasal irritation possible. Additional cognitive / neurological monitoring at baseline and 6–8 week follow-up is appropriate.

Clinical Evidence

Primary

DSIP — characterisation and effects on sleep

PMID 6324019

DSIP (Intranasal) vs Related Peptides

Compound	Profile	Onset	Best For
DSIP (Intranasal)	Neuropeptide (sleep, intranasal)	Rapid CNS uptake via olfactory route	Neuroprotection
Semax	ACTH-derived nootropic heptapeptide	CNS effect hours; plasma minutes	A Russian-developed analogue of ACTH(4-10) extended with a Pro-Gly-Pro tail for proteolytic stability — a clinically used nootropic and stroke recovery agent
Selank	Tuftsin-derived heptapeptide anxiolytic	CNS effect lasts hours; plasma short	A Russian-developed heptapeptide derived from tuftsin — anxiolytic without sedation, supported by clinical trial data in generalised anxiety disorder
DSIP	Neuropeptide (sleep)	~7 min plasma; CNS effects longer	A short neuropeptide isolated from sleeping rabbits in 1977, of interest for its modulation of delta-wave sleep and stress resilience
Pinealon	Khavinson tripeptide (pineal-derived)	Short plasma; durable tissue effects	A Khavinson pineal-derived tripeptide of glutamate-aspartate-arginine, studied for neuroprotection and cognitive function in aged and ischemic models

Frequently Asked Questions

Can DSIP (Intranasal) be stacked with other nootropics?

Yes, and it is commonly paired. The cleanest pairings are with compounds on complementary pathways — anxiolytic (selank), neurotrophic (semax), sleep-architecture (DSIP), or anti-inflammatory (LL-37) — rather than with other compounds engaging the same pathway.

Best route for cognitive applications — injection or intranasal?

For most DSIP (Intranasal) cognitive use cases, the route that delivers the compound closest to its target site of action is preferred. Intranasal delivery via the olfactory pathway is the standard for direct CNS access where available.

Is DSIP (Intranasal) a true nootropic?

Not in the caffeine-or-modafinil sense. DSIP (Intranasal) does not acutely sharpen attention or working memory in healthy users. Its cognitive value is restorative — supporting recovery from neurological injury, reducing chronic neuroinflammation, and stabilising the upstream systems that cognitive function depends on.

Cognitive side effects to watch for?

Reported issues are uncommon in animal and limited human data but include mild sedation, vivid dreams, transient mood lability in the first week, and infrequent headache. There are no large-scale human safety trials. Discontinue if mood symptoms are concerning and re-evaluate.

What is DSIP (Intranasal)?

DSIP (Intranasal) (also known as Delta Sleep-Inducing Peptide — Nasal) is a 9-residue neuropeptide (sleep, intranasal) with a molecular weight of 848 Da and a plasma half-life of Rapid CNS uptake via olfactory route. Same DSIP molecule delivered intranasally. The olfactory and trigeminal nerve pathways allow direct CNS access, sidestepping the BBB and producing faster onset on sleep-relevant brain regions. The compound is studied primarily in the cognitive / neurological domain for the applications outlined above.

What is the evidence base for DSIP (Intranasal)?

DSIP (Intranasal)'s evidence base sits at preclinical. The references on this page summarise 1 primary publication supporting the principal mechanism and applications. Where Phase II or Phase III human data exists for related indications, it is cited; where evidence is preclinical or limited to small case series, that is noted. The cognitive / neurological interpretation respects the actual evidence tier rather than over-stating mechanistic plausibility.

Clinical Protocol

Start a DSIP (Intranasal) Protocol

Alukard provides physician-supervised cognitive protocols with GMP-certified DSIP (Intranasal) and GMP-certified compounds and comprehensive neurological assessments.

Get Protocol

Quick Facts

Molecular weight: 848 Da
Sequence length: 9 aa
Half-life: Rapid CNS uptake via olfactory route
WADA: Not on prohibited list
FDA: Unapproved
Research: Preclinical

Stack Partners

Semax

Selank

Semax + Selank Blend

DSIP

LL-37

Research Note

All cognitive / neurological applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for DSIP (Intranasal) unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.

Physician-supervised cognitive protocols

Start Your Cognitive / Neurological Protocol for DSIP (Intranasal)

Alukard provides physician-supervised cognitive protocols with GMP-certified compounds and comprehensive neurological assessments.

Get a Physician Consultation View All Compounds

HIPAA Compliant · GMP Certified · Physician Supervised